19 / 28
Page 54
conferenceseries
.com
Volume 08
Journal of Alzheimers Disease & Parkinsonism
Alzheimer's Congress 2018
May 30-31, 2018
May 30-31, 2018 Osaka, Japan
10
th
World Congress on
Alzheimer's Disease & Dementia
Perspective on neurobiological and clinical early indicators of mild cognitive decline and alzheimer’s
disease
Jigar Jogia
American University in Dubai, UAE
T
here is a need for early diagnosis, monitoring and treatment of Alzheimer’s Disease (AD) and Mild Cognitive Impairment
(MCI). Traditional assessments of cognitive decline have been found to lack sensitivity and accuracy in differentiating
varying stages of Dementia and cognitive decline as well as being time consuming in their administration. Key components
of cognition namely memory and executive function have been identified as most predicative of AD status. Brief cognitive
screening tools such as the Montreal cognitive assessment have been recommended both as a primary clinical and research
assessment offering more sensitivity in differentiating AD and MCI. However, overlapping clinical features and impairments in
cognitive processing suggest a need for biological risk factors. Neurobiological indicators of cognitive deterioration have been
identified implicating measures of cerebrospinal fluid and temporal lobe atrophy as potential biomarkers of early clinical phases
of AD and predictors of cognitive decline. Evidence shows the utility of automated classification methods in processing and
analyzing multivariate neuroimaging data which improves our accuracy for the prediction of conversion of MCI to AD. In this
review, we discuss the clinical usefulness of such approaches and the need for big data and multi-site studies in improving our
understanding of AD neuropathology and confirming pathophysiological mechanisms that can reliably be used to differentiate
MCI and AD and predict disease progression and cognitive decline.
jjogia@aud.eduJ Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C4-046